International recognition for pioneering work in translational research and personalized medicine for breast cancer

Agendia’s MammaPrint® has been acknowledged by the medical community, as well as other prominent organizations, for its role in the advancement of breast cancer research and diagnostics as well as its contributions in the movement toward personalized medicine.

2011 Agendia wins Scrip Award for “Best Partnership Alliance”

Agendia is a recipient of the 2011 Scrip Award for “Best Partnership” for its cooperative alliance between Agendia, AstraZeneca and the Netherlands Cancer Institute (NKI).

2009 St. Gallen’s International Oncology Guidelines

MammaPrint added to the St. Gallen’s International Oncology Guidelines for Primary Therapy of Early Breast Cancer.

2008 Dutch Government’s Healthcare Innovation Platform

MammaPrint test declared “One of the Most Pioneering Healthcare Innovations” in the 21st Century by the Dutch Government’s Healthcare Innovation Platform.

2008 MammaPrint included in The Dutch Institute for Healthcare Improvement CBO Guidelines

MammaPrint has been included in the updated 2008 guidelines of The Dutch Institute for Healthcare Improvement CBO. The CBO guidelines, drafted in collaboration with the Dutch Association of Comprehensive Cancer Centers (ACCC) and the Dutch National Breast Cancer Consultation Group (NABON). MammaPrint will be offered as standard of care for all eligible early stage breast cancer patients at the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL).

2007 FDA Clearance

The U.S. Food & Drug Administration granted the first and only IVDMIA clearance to the MammaPrint breast cancer gene expression profile. On June 22, Agendia acquired the second MammaPrint FDA clearance for use with its RNARetain room temperature tissue fixative for molecular testing.

2007 Estee Lauder

Dr. Laura van ‘t Veer, Co-founder and Chief Research Officer of Agendia, received the 2007 Breast Cancer Research Foundation Award from the Estee Lauder Pink Ribbon Breast Cancer Research Foundation.

2007 The Frost & Sullivan European Product Innovation Award

The Frost & Sullivan European Product Innovation Award in the field of biomarker based breast cancer diagnostics was presented to Agendia for its new method of translating a breast cancer prognosis microarray signature into a high-throughput diagnostic test called MammaPrint.

2007 TIME Magazine

TIME Magazine chose MammaPrint as one of the “Five Best Healthcare Inventions of the Year” naming it “Cancer’s Crystal Ball.

2007 ESMO Lifetime Achievement Award

Dr. Laura van ‘t Veer received the 2007 European Society of Medical Oncology (ESMO) Lifetime Achievement Award for her work in translational research in breast cancer and the development of MammaPrint.